In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FibroGen Inc.

www.fibrogen.com

Latest From FibroGen Inc.

Approval Positions Roxadustat As Japan HIF-PHI Pioneer

The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.

Japan Approvals

AstraZeneca Buys Priority Review Voucher With Two Big Filings On The Horizon

AstraZeneca paid $95m to Swedish Orphan Biovitrum for the voucher, which it could use to expedite the FDA review of roxadustat or trastuzumab deruxtecan.

Drug Review Launches

Vadadustat Emerges As Japan HIF-PHI Contender With First Filing Globally

Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.

Japan Commercial

Positive Results Move Anemia Contender Enarodustat Towards First Filing

Japanese firms unveil pivotal top-line results that pave way for first filing of novel anemia therapy within new class of agents, but competition is high and timings remain unclear.

Japan Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Hepatic (Liver)
  • Musculoskeletal & Connective Tissue Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • FibroGen Inc.
  • Senior Management
  • James A Schoeneck, Interim CEO
    Pat Cotroneo, VP, Fin. & CFO
    David M Dimmick, MD, VP, Quality
    R. Wayne Frost, VP, RA
    Elias Kouchakji, MD, VP, Clinical Dev and Drug Safety
    AI Lin, MD, PhD, VP, Drug Dev.
    Peony K Yu, CMO
  • Contact Info
  • FibroGen Inc.
    Phone: (415) 978-1200
    409 Illinois St.
    San Francisco, CA 94158
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register